Treated chronic hepatitis B is a good prognostic factor of diffuse large B-cell lymphoma
Last Updated: Monday, September 25, 2023
Findings from a recent analysis of patients with hepatitis B virus (HBV)–associated vs HBV-unassociated DLBCL indicated that those with HBV-associated disease receiving antiviral treatment have significantly longer time to progression (adjusted HR 0.49, 95% CI 0.29–0.82, P=0.007) and overall survival (HR 0.55, 95% CI 0.33–0.92, log-rank P=0.02) after R-CHOP treatment than those with HBV-unassociated disease.
Advertisement
News & Literature Highlights
